Bisphosphonate Use in Chronic Kidney Disease: Association with Adynamic Bone Disease in a Bone Histology SeriesAmerling R.a, c · Harbord N.B.a, c · Pullman J.b, c · Feinfeld D.A.a, c
aDivision of Nephrology and Hypertension, Department of Medicine, Beth Israel Medical Center, bDepartment of Pathology, Montefiore Medical Center, and cAlbert Einstein College of Medicine, New York, N.Y., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Dual X-ray absorptiometry is the standard diagnostic modality for identification of low bone mineral density, a finding which is in the general population usually indicative of osteopenia or osteoporosis. However, chronic kidney disease (CKD) patients diagnosed with osteopenia or osteoporosis may in actual fact have renal osteodystrophy with high or low bone turnover. While bisphosphonates are currently prescribed for the prevention of fractures in osteoporosis and high-risk osteopenic patients, the clinical utility of bisphosphonate therapy in CKD has not been established. Furthermore, bisphosphonates accumulate in bone, inhibit osteoclasts, and may cause or exacerbate low-turnover (adynamic) bone disease – particularly in patients presenting with low parathyroid hormone (PTH) levels or receiving treatment for secondary hyperparathyroidism. Bone biopsy with non-decalcified histopathology remains the gold standard for the identification and evaluation of bone disorders, including osteoporosis and renal osteodystrophy. Thirteen CKD patients (stage II–IV), referred to our clinic over a 12-month period, were identified as having taken bisphosphonates from 4 to >60 months after a diagnosis of osteopenia or osteoporosis. All patients underwent biopsies of trabecular bone from the iliac crest following oral administration of time-separated doses of doxycycline and tetracycline. Bone pathology was assessed after processing for mineralized histology. For all patients, clinical data collection included assessment of likely causes of kidney disease, MDRD glomerular filtration rate, calcium-phosphate product, intact PTH level, alkaline phosphatase, and bisphosphonate exposure. All 13 patients were diagnosed with adynamic bone on biopsy evaluation. Eleven biopsies revealed decreased cancellous bone mass; 8 showed decreased osteoid surface; 8 disclosed decreased osteoid thickness, and all 13 demonstrated low or low-normal osteoclast/osteoblast interface. Assessment of dynamic bone formation demonstrated decreased or absent single- or double-labeled osteoid in all 13 bone specimens. Based on these observations, the use of bisphosphonates in CKD cannot be recommended.
© 2010 S. Karger AG, Basel
- Centers for Disease Control and Prevention (CDC): Prevalence of chronic kidney disease and associated risk factors – United States, 1999–2004. MMWR Morb Mortal Wkly Rep 2007;56:161–165.
- Moe S, Drüeke T, Cunningham J, et al: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945–1953.
- Feinfeld DA, Sherwood LM: Parathyroid hormone and 1,25-(OH)2D3 in chronic renal failure. Kidney Int 1988;33:1049–1058.
Osteoporosis Prevention, Diagnosis, and Therapy, NIH Consensus Statement, 2000, March 27–29 (http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hsnihcdc& part=A20225).
WHO Definition of Osteoporosis.
- Stafford RS, Drieling RL, Hersh AL: National trends in osteoporosis visits and osteoporosis treatment, 1988–2003. Arch Intern Med 2004;164:1525–1530.
- Lin JH: Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75–85.
- Lasseter KC, Porras AG, Denker A, et al: Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. Clin Drug Investig 2005;25:107–114.
- Linnebur SA, Milchak JL: Assessment of oral bisphosphonate use in elderly patients with varying degrees of kidney function. Am J Geriatr Pharmacother 2004;2:213–218.
- Miller PD, Roux C, Boonen S, , et al: Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005;20:2105–2115.
- Gipson D, Katz LA, Stehman-Breen C: Principles of dialysis: special issues in women. Semin Nephrol 1999;19:140–147.
- Schmidt A, Luger A, Horl WH: Sexual hormone abnormalities in male patients with renal failure. Nephrol Dial Transplant 2002;17:368–371.
- Suzuki T, Nagai H, Yoshida H, et al: Appropriateness and limitations of bone mineral measurements by DXA (dual energy X-ray absorptiometry) in the elderly – comparison with X-ray findings. Nippon Koshu Eisei Zasshi 1995;42:385–397.
- Jones G, Nguyen T, Sambrook PN, et al: A longitudinal study of the effect of spinal degenerative disease on bone density in the elderly. J Rheumatol 1995;22:932–936.
- Ensrud KE, Lui LY, Taylor BC, et al: Osteoporotic Fractures Research Group. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 2007;167:133–139.
- Nickolas TL, McMahon DJ, Shane E: Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 2006;17:3223–3232.
- Fried LF, Biggs ML, Shlipak MG: Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 2007;18:282–286.
- Rodriguez Garcia M, Gomez Alonso C, Naves Diaz M, et al: Prevalence of vertebral fractures and aortic calcifications in hemodialysis patients: comparison with a population of the same age and sex. Nefrologia 2003;23(suppl 2):106–111.
- Rix M, Andreassen H, Eskildsen P, et al: Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999;56:1084–1093.
- Klawansky S, Komaroff E, Cavanaugh PF, et al: Relationship between age, renal function and bone mineral density in the US population. Osteoporosis Int 2003;14:570–576.
- Hsu CY, Cummings SR, McCulloch CE, et al: Bone mineral density is not diminished by mild to moderate chronic renal insufficiency. Kidney Int 2002;61:1814–1820.
- Lobao R, Carvalho AB, Cuppari L, et al: High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol 2004;62:432–439.
- Miller PD: Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 2005;3:5–12.
- Schwarz C, Sulzbacher I, Oberbauer R: Diagnosis of renal osteodystrophy. Eur J Clin Invest 2006;36:13–22.
- Liberman UA, Weiss SR, Broll J, et al: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437–1443.
- Cummings SR, Black DM, Thompson DE, et al: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077–2082.
- Harris ST, Watts NB, Genant HK, et al: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–1352.
- Russell RG, Rogers MJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97–106.
- Reszka AA, Rodan GA: Mechanism of action of bisphosphonates. Curr Osteoporos Rep 2003;1:45–52.
- Ott S: Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90:1897–1899.
- Cunningham J: Bisphosphonates in the renal patient. Nephrol Dial Transplant 2007;22:1505–1507.
- Porras AG, Holland SD, Gertz BJ: Pharmacokinetics of alendronate. Clin Pharmacokinet 1999;36:315–328.
- Ensrud KE, Barret-Connor EL, Schwartz A, et al: Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004;19:1259–1269.
- Chevassieux PM, Arlot ME, Reda C, et al: Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475–1480.
- Eriksen EF, Melsen F, Sod E, et al: Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002;31:620–625.
- Mashiba T, Turner CH, Hirano T, et al: Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28:524–531.
- Odvina CV, Zerwekh JE, Rao DS, et al: Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294–1301.
- Kodras K, Haas M: Effect of kidney transplantation on bone. Eur J Clin Invest 2006;36(suppl 2):63–75.
- Mitterbauer C, Schwarz C, Haas M, et al: Effects of bisphosphonates on bone loss in the first year after renal transplantation – a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006;21:2275–2281.
- Palmer SC, Strippoli GF, McGregor DO: Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis 2005;45:638–649.
- Coco M, Glicklich D, Faugere MC, et al: Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003;14:2669–2676.
- Velasquez-Forero F, Mondragón A, Herrero B, et al: Adynamic bone lesion in renal transplant recipients with normal renal function. Nephrol Dial Transplant 1996;11(suppl 3): 58–64.
- Kurz P, Monier-Faugere MC, Bognar B, et al: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994;46:855–861.
- Moe SM: Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 2006;36(suppl 2): 51–62.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.